PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
PALVELLA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$122.96+2.66 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.8%
14M of 14M shares
Institutional holders
197
38 new, 19 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 43 sales
Net sold $8.87M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Prudential Financial Inc | 962,374 | 6.70% | 13G (passive) | Jun 30, 2026 |
| Jennison Associates LLC | 960,619 | 6.70% | 13G (passive) | Jun 30, 2026 |
| Mathew P. Arens | 887,031 | 7.49% | 13G (passive) | Dec 31, 2025 |
| Bvf Inc/Il | 879,009 | 7.10% | 13G (passive) amendment | Dec 31, 2025 |
| Suvretta Capital Management, LLC | 822,400 | 7.40% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 812,953 | 5.70% | 13G (passive) | Jun 30, 2026 |
| First Light Asset Management, LLC | 769,117 | 5.34% | 13G (passive) amendment | Jun 30, 2026 |
| Aaron Cowen | 714,463 | 8.60% | 13G (passive) | Dec 13, 2024 |
| Fhmlsp, L.L.C. | 706,360 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Patrick J. Heron | 690,012 | 6.30% | 13G (passive) amendment | Mar 31, 2025 |
| Srinivas Akkaraju | 679,486 | 6.10% | 13G (passive) | Dec 13, 2024 |
| James N. Topper | 575,892 | 5.10% | 13G (passive) | Dec 13, 2024 |
| Kaupinen Wes | 1,644,869 | 14.60% | 13D (active) | Dec 13, 2024 |
| ADAR1 Capital Management, LLC | 138,641 | 10.50% | 13G (passive) | Jul 24, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PVLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 1,135,406 | 7.88% | $173.51M | −18,090 | 3.17% |
| Jennison Associates LLC | 960,619 | 6.67% | $146.80M | +320,008 | 0.09% |
| BlackRock, Inc. | 918,357 | 6.37% | $140.34M | +231,504 | 0.00% |
| Frazier Life Sciences Management, L.P. | 882,400 | 6.12% | $134.85M | – | 2.94% |
| First Light Asset Management, LLC | 771,901 | 5.36% | $117.96M | −208,857 | 7.17% |
| Bvf Inc/Il | 672,789 | 4.67% | $102.82M | −288,200 | 2.63% |
| State Street Corp | 653,172 | 4.53% | $99.82M | +194,173 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 638,868 | 4.43% | $97.63K | +236,304 | 0.01% |
| Vanguard Capital Management LLC | 513,794 | 3.57% | $78.52M | +36,500 | 0.00% |
| Frontier Capital Management Co LLC | 478,833 | 3.32% | $73.18M | +104,798 | 0.68% |
| Federated Hermes, Inc. | 433,015 | 3.01% | $66.17M | – | 0.10% |
| Woodline Partners LP | 317,517 | 2.20% | $48.52M | – | 0.15% |
| Orbimed Advisors LLC | 292,360 | 2.03% | $44.68M | +157,760 | 0.83% |
| Geode Capital Management, LLC | 276,164 | 1.92% | $42.21M | +70,555 | 0.00% |
| Siren, L.L.C. | 257,485 | 1.79% | $39.35M | – | 0.80% |
| Primecap Management Co/Ca/ | 256,182 | 1.78% | $39.15M | +61,152 | 0.02% |
| Alliancebernstein L.P. | 253,168 | 1.76% | $31.56M | −9,667 | 0.01% |
| Eventide Asset Management, LLC | 231,484 | 1.61% | $35.38M | −1,764 | 0.47% |
| Emerald Advisers, LLC | 229,486 | 1.59% | $35.07M | +67,986 | 0.83% |
| FMR LLC | 214,841 | 1.49% | $32.83M | −967 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 197 | 14M | 97.8% | 38 / 89 | 43 / 19 | 2M | 2M |
| Q1 2026 | 180 | 13M | 92.0% | 65 / 65 | 30 / 22 | 5M | 1M |
| Q4 2025 | 140 | 10M | 67.7% | 53 / 41 | 30 / 12 | 3M | 2M |
| Q3 2025 | 100 | 9M | 59.2% | 43 / 23 | 20 / 8 | 4M | 1M |
| Q2 2025 | 65 | 6M | 41.0% | 26 / 19 | 9 / 2 | 2M | 1M |
| Q1 2025 | 41 | 5M | 35.6% | 15 / 9 | 4 / 7 | 1M | 0M |
| Q4 2024 | 33 | 4M | 28.0% | 33 / 0 | 0 / 0 | 4M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PVLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 408,678 | 2.84% | $62.45M | 0.58% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 388,390 | 2.70% | $59.35M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 281,586 | 1.95% | $43.03M | 0.05% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 276,556 | 1.92% | $38.45M | 0.78% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 231,484 | 1.61% | $35.38M | 1.98% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 209,825 | 1.46% | $29.17M | 0.39% | Jul 31, 2026 |
| PGIM Jennison Small Company Fund | 202,900 | 1.41% | $31.01M | 0.89% | Jun 30, 2026 |
| PGIM Jennison Health Sciences Fund | 183,037 | 1.27% | $21.68M | 1.56% | May 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 164,144 | 1.14% | $25.08M | 0.17% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 150,500 | 1.04% | $20.93M | 0.73% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 144,220 | 1.00% | $22.04M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 143,740 | 1.00% | $19.99M | 0.23% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 120,068 | 0.83% | $16.69M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 113,586 | 0.79% | $17.36M | 0.02% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 109,498 | 0.76% | $16.73M | 0.53% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Wes Kaupinen | President and CEO, Director, 10% owner | 1,607,228 | 11.15% | Feb 9, 2026 |
| Kathleen Goin | Chief Operating Officer | 4,302 | 0.03% | Sep 18, 2026 |
| Matthew E. Korenberg | CFO, Treasurer | 1,000 | 0.01% | Jun 16, 2026 |
| Ashley Hartmann Kline | Chief Commercial Officer | – | – | Feb 9, 2026 |
| Jeffrey S. Martini | Chief Scientific Officer | – | – | Feb 9, 2026 |
| Palvella Therapeutics, Inc. | CFO and Treasurer | – | – | Feb 7, 2025 |
| George M. Jenkins | Director | 174,192 | 1.21% | Sep 15, 2026 |
| Christopher P. Kiritsy | Director | 250 | 0.00% | Sep 4, 2026 |
| Matthew Pauls | Director | – | – | Jul 1, 2026 |
| John Doux | Director | – | – | Jun 12, 2026 |
| Tadd S. Wessel | Director | – | – | Jun 12, 2026 |
| Elaine J. Heron | Director | 53,691 | 0.37% | Jun 12, 2026 |
| Todd C. Davis | Director | 112,547 | 0.78% | Jun 12, 2026 |
| James A. Geraghty | Director | 0 | – | Dec 12, 2024 |
| Value Fund L. P. Biotechnology | – | 772,324 | 5.36% | Dec 17, 2024 |
| Ii Gp Llc Bvf | – | – | – | Dec 17, 2024 |
| Partners L. P/Il Bvf | – | – | – | Dec 17, 2024 |
| Mark N. Lampert | – | 425,346 | 2.95% | Dec 17, 2024 |
| Value Trading Fund OS LP Biotechnology | – | – | – | Dec 17, 2024 |
| Partners OS Ltd. BVF | – | 2,233,074 | 15.50% | Dec 17, 2024 |
| Value Fund Ii Lp Biotechnology | – | – | – | Dec 17, 2024 |
| I. Gp Llc Bvf | – | 282,223 | 1.96% | Dec 17, 2024 |
| Inc/Il Bvf | – | 2,408,207 | 16.71% | Dec 17, 2024 |
| Gp Holdings Llc Bvf | – | 8,581,171 | 59.56% | Dec 17, 2024 |
| Investments LP Dellora | – | 141,079 | 0.98% | Dec 16, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −1,659 | $151.16 | $250.77K | 2,643 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −989 | $152.36 | $150.68K | 1,654 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −1,654 | $153.24 | $253.46K | 0 |
| George M. Jenkins Director | Sep 15, 2026 | Sale(10b5-1 plan) | −263 | $150.40 | $39.56K | 160,676 |
| George M. Jenkins Director | Sep 15, 2026 | Sale(10b5-1 plan) | −954 | $149.38 | $142.51K | 160,939 |
| George M. Jenkins Director | Sep 15, 2026 | Sale(10b5-1 plan) | −560 | $151.33 | $84.74K | 160,116 |
| George M. Jenkins Director | Sep 14, 2026 | Sale(10b5-1 plan) | −1,560 | $153.10 | $238.84K | 161,893 |
| George M. Jenkins Director | Sep 14, 2026 | Sale(10b5-1 plan) | −6,160 | $152.12 | $937.06K | 163,453 |
| George M. Jenkins Director | Sep 14, 2026 | Sale(10b5-1 plan) | −5,632 | $151.46 | $853.02K | 169,613 |
| George M. Jenkins Director | Sep 11, 2026 | Sale(10b5-1 plan) | −6,520 | $150.62 | $982.04K | 181,096 |
| George M. Jenkins Director | Sep 11, 2026 | Sale(10b5-1 plan) | −4,577 | $151.72 | $694.42K | 176,519 |
| George M. Jenkins Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,274 | $153.06 | $195.00K | 175,245 |
| Christopher P. Kiritsy Director | Sep 2, 2026 | Sale | −313 | $157.00 | $49.14K | 250 |
| Christopher P. Kiritsy Director | Sep 2, 2026 | Option exercise | +313 | $127.20 | $39.81K | 563 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −302 | $156.77 | $47.34K | 0 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −1,500 | $151.39 | $227.08K | 2,802 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −1,998 | $151.80 | $303.30K | 804 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −400 | $153.00 | $61.20K | 404 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −102 | $155.59 | $15.87K | 302 |
| Kathleen Goin Chief Operating Officer | Jul 15, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Jul 15, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −522 | $147.14 | $76.81K | 3,780 |
| Kathleen Goin Chief Operating Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −840 | $148.40 | $124.66K | 2,940 |
| Kathleen Goin Chief Operating Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −1,029 | $149.27 | $153.60K | 1,911 |
| Kathleen Goin Chief Operating Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −1,911 | $150.25 | $287.13K | 0 |
| Kathleen Goin Chief Operating Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −1,887 | $111.31 | $210.04K | 25 |
| Kathleen Goin Chief Operating Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −2,390 | $110.26 | $263.52K | 1,912 |
| Kathleen Goin Chief Operating Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −25 | $112.23 | $2.81K | 0 |
| Kathleen Goin Chief Operating Officer | Jun 17, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Jun 17, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Matthew E. Korenberg CFO, Treasurer | Jun 12, 2026 | Option exercise | +1,000 | $13.60 | $13.60K | 1,000 |
| Kathleen Goin Chief Operating Officer | May 20, 2026 | Sale(10b5-1 plan) | −891 | $111.30 | $99.17K | 48 |
| Kathleen Goin Chief Operating Officer | May 20, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | May 20, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | May 20, 2026 | Sale(10b5-1 plan) | −3,363 | $110.35 | $371.11K | 939 |
| Kathleen Goin Chief Operating Officer | May 20, 2026 | Sale(10b5-1 plan) | −48 | $111.90 | $5.37K | 0 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −1,502 | $125.96 | $189.19K | 2,800 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −1,500 | $127.13 | $190.70K | 1,300 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −561 | $128.23 | $71.94K | 739 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −639 | $129.17 | $82.54K | 100 |
| Kathleen Goin Chief Operating Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −100 | $130.33 | $13.03K | 0 |
| George M. Jenkins Director | Mar 30, 2026 | Buy | +445 | $112.30 | $49.97K | 187,616 |
| Kathleen Goin Chief Operating Officer | Mar 18, 2026 | Sale(10b5-1 plan) | −304 | $119.08 | $36.20K | 0 |
| Kathleen Goin Chief Operating Officer | Mar 18, 2026 | Sale(10b5-1 plan) | −1,730 | $118.37 | $204.78K | 304 |
| Kathleen Goin Chief Operating Officer | Mar 18, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Mar 18, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Mar 18, 2026 | Sale(10b5-1 plan) | −2,268 | $117.56 | $266.63K | 2,034 |
| George M. Jenkins Director | Feb 27, 2026 | Buy | +4,000 | $125.00 | $500.00K | 187,171 |
| Elaine J. Heron Director | Feb 27, 2026 | Buy | +2,400 | $125.00 | $300.00K | 47,812 |
| Kathleen Goin Chief Operating Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −1,276 | $79.97 | $102.04K | 0 |
| Kathleen Goin Chief Operating Officer | Feb 18, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Feb 18, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −3,026 | $79.16 | $239.54K | 1,276 |
| Kathleen Goin Chief Operating Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −553 | $95.49 | $52.81K | 3,749 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| George M. Jenkins Director | Oct 13, 2026 | 27,500 | $3.70M | Oct 13, 2026 | Private Investment |
| Kathleen Goin Officer | Sep 16, 2026 | 4,302 | $650.55K | Sep 16, 2026 | Stock Option Exercise |
| George M. Jenkins Director | Sep 11, 2026 | 27,500 | $4.14M | Sep 11, 2026 | Private Investment |
| Kiritsy Christopher Director | Sep 2, 2026 | 375 | $58.88K | Sep 2, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Aug 19, 2026 | 4,302 | $647.11K | Aug 19, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Jul 15, 2026 | 4,302 | $643.92K | Jul 15, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Jun 17, 2026 | 4,302 | $476.37K | Jun 17, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | May 20, 2026 | 4,302 | $475.63K | May 20, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Apr 15, 2026 | 4,302 | $557.24K | Apr 15, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Mar 18, 2026 | 4,302 | $519.68K | Mar 18, 2026 | Stock Option |
| Kathleen Goin Officer | Feb 19, 2026 | 4,302 | $344.55K | Feb 18, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Feb 18, 2026 | 4,301 | $344.47K | Feb 18, 2026 | Option Exercise |
| Kathleen Goin Officer | Jan 21, 2026 | 4,302 | $421.64K | Jan 21, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Dec 17, 2025 | 4,302 | $416.48K | Dec 17, 2025 | Stock Option Exercise |
| Kathleen Goin Officer | Nov 19, 2025 | 4,302 | $356.81K | Nov 19, 2025 | Stock Option Exercise |